Bobby Swinney, DO
Internal Medicine · Ocean Springs, MSNPI 1528421484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 569 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,485 and has fallen 59.6% since, to $1,005 in 2025. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 569 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Viiv Healthcare Company$1K
- AbbVie$1K
- Novo Nordisk$920
- Lilly USA, LLC$666
- plus $2K from 34 others
What the payments were for
- Food & beverage$9,615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,562 |
| GSK | 114 | $1,426 |
| Viiv Healthcare Company | 75 | $1,409 |
| AbbVie(2 entities) | 78 | $1,276 |
| Novo Nordisk | 61 | $920 |
| Lilly USA, LLC | 43 | $666 |
| Gilead | 26 | $309 |
| Pfizer | 18 | $279 |
| Boehringer Ingelheim | 11 | $173 |
| Corcept Therapeutics | 5 | $171 |
| Johnson & Johnson(2 entities) | 9 | $158 |
| Renalytix AI, Inc. | 9 | $150 |
| Daiichi Sankyo Inc. | 7 | $118 |
| Astellas Pharma US Inc | 6 | $103 |
| Amgen(2 entities) | 6 | $103 |
| GRT US Holding, Inc. | 1 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $81 |
| Biohaven Pharmaceuticals, Inc. | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Averitas Pharma Inc. | 2 | $43 |
| Boston Scientific | 1 | $36 |
| Exact Sciences | 2 | $30 |
| Genentech USA, Inc. | 2 | $28 |
| Bayer | 2 | $28 |
| Merck | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Novartis | 2 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Medtronic | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,615 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $169,203 |
| MounjaroTirzepatide | 124 | $158,658 |
| EliquisApixaban | 70 | $69,968 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $50,139 |
| TrulicityDulaglutide | 32 | $46,308 |
| JardianceEmpagliflozin | 36 | $45,943 |
| FarxigaDapagliflozin Propanediol | 39 | $36,696 |
| XareltoRivaroxaban | 38 | $32,040 |
| JanuviaSitagliptin Phosphate | 24 | $25,889 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $20,510 |
| LinzessLinaclotide | 31 | $15,712 |
| EntrestoSacubitril/Valsartan | 15 | $15,122 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,396 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $11,688 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $8,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $666 | $204,966156 claims |
| Novo NordiskOzempic | $920 | $169,203144 claims |
| PfizerEliquis | $279 | $69,96870 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,426 | $61,82784 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,562 | $56,60874 claims |
| Boehringer IngelheimJardiance | $173 | $45,94336 claims |
| MerckJanuvia, Janumet | $24 | $32,91436 claims |
| Johnson & JohnsonXarelto | $158 | $32,04038 claims |
| AbbVieLinzess, Synthroid | $1,276 | $17,68970 claims |
| NovartisEntresto | $24 | $15,12215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Ocean Springs
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
- Charles HillOxford$15K
- Paul VolanskyCorinth$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.